what is in glp-1 Agonists - it? PDB-101: Molecule of the Month:
Description
Prevention of diet-induced obesity: healthy, nonobese animals at baseline receiving experimental treatment while receiving a high-fat diet
*For weight loss-related consultation only
GLP-1RAs commonly cause gastrointestinal side effects that are dose-dependent and typically settle once the dose stabilizes
10.1016/j.peptides.2017.12.002 Peptides 4 ArnaoutM
Question 4: what other conditions besides obesity may contribute to the development of hepatic steatosis
In addition, Mazdutide showed a reduction in liver fat content of 80.2% in patients with a high baseline liver fat concentration
